Iovance Biotherapeutics recently announced that its tumor-infiltrating lymphocyte (TIL) therapy for soft tissue sarcoma has achieved positive results in its first clinical trial.
Show original
This groundbreaking development marks a key step forward for TIL cell therapy in the treatment of solid tumors, bringing new hope for patients with soft tissue sarcoma.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Odaily Noon News
Odaily星球日报•2026/02/27 05:33
Base ecosystem Flow Protocol completes Agent-exclusive auction, raising over $100,000 in 9 minutes
BlockBeats•2026/02/27 05:30
City Protocol Virality Leaderboard goes live, with the first $20,000 prize pool now open
BlockBeats•2026/02/27 05:22
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$67,794.22
-0.72%
Ethereum
ETH
$2,045.03
-0.73%
Tether USDt
USDT
$1.0000
-0.00%
XRP
XRP
$1.41
-2.23%
BNB
BNB
$632.1
+0.79%
USDC
USDC
$1
+0.05%
Solana
SOL
$87.68
+0.30%
TRON
TRX
$0.2851
-0.66%
Dogecoin
DOGE
$0.09879
-1.17%
Cardano
ADA
$0.2944
+0.24%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now